TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06785571
Drug: Nalbuphine hydrochloride injection
Normalized name: nalbuphine hydrochloride Injection
DrugBank: Nalbuphine (DB00844)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: a loading dose of Nalbuphine hydrochloride injection administered in 30 ±10 seconds, followed by a maintenance dose of 2.0mg/h (a recommended maintenance dose range of 1.0\~5.0mg/h)
Study: NCT06785571
Drug: Hydromorphone hydrochloride injection
Normalized name: Hydromorphone Hydrochloride Injection
DrugBank: Hydromorphone (DB00327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A maintenance dose of 0.5mg/h (a recommended maintenance dose range of 0.5\~3.0mg/h)
Study: NCT06783309
Drug: CNP-103
Normalized name: TransCon CNP
DrugBank: ACP-015 (DB17824)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CNP-103
Study: NCT06581380
Drug: Topotecan
Normalized name: Topotecan
DrugBank: Topotecan (DB01030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topotecan will be administered per drug label.
Study: NCT06795165
Drug: Moxidectin 2 MG Oral Tablet
Normalized name: moxidectin 2 mg ORAL TABLET
DrugBank: Moxidectin (DB11431)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: active medication
Study: NCT06788626
Drug: Semaglutide 0.5 mg
Normalized name: semaglutide 0.5 MG/ML
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 0.5mg semaglutide injection before and 1 week after endovascular treatment.
Study: NCT06740422
Drug: Xuanhuang Runtong Tablet Simulator
Normalized name: bisacodyl
DrugBank: Bisacodyl (DB09020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Xuanhuang Runtong Tablet Simulator
Study: NCT06797193
Drug: Perflutren Lipid Microspheres
Normalized name: perflutren lipid microspheres
DrugBank: Perflutren (DB00556)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT06795893
Drug: Anifrolumab
Normalized name: ANIFROLUMAB
DrugBank: Anifrolumab (DB11976)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Anifrolumab is a human monoclonal antibody that binds to subunit 1 of the type 1 interferon receptor,which was developed based on the evidence supporting the role of type 1 interferon pathway in SLE. Clinical trial evidence from TULIP 1 and TULIP 2 have showed that monthly intravenous administration of anifrolumab led to a higher percentage of patients with a response, assessed with the British Isles Lupus Assessment Group-based Composite Lupus Assessment, compared with patients receiving placebo. Moreover, the phase II MUSE study showed that administration of anifrolumab resulted in substantially reduce disease activity, as measured by the SLE Responder Index,compared to patients receiving placebo. Anifrolumab was approved by the FDA and EMA in July 2021 and February 2022,respectively, for the treatment of adult patients with moderate to severe SLE who are receiving standard therapy.
Study: NCT06797505
Drug: PEG-rhGH with new preparation (T)
Normalized name: RhGH-PEG
DrugBank: Lonapegsomatropin (DB16220)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: A single subcutaneous injection of PEG-rhGH with new preparation
Study: NCT06797505
Drug: PEG-rhGH with present preparation (T)
Normalized name: cranberry preparation
DrugBank: Cranberry (DB10631)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single subcutaneous injection of PEG-rhGH with present preparation
Study: NCT06794645
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: pembrolizumab 200 mg by intravenous (IV) infusion on Day 1 of each 21-day treatment cycle
Study: NCT06794645
Drug: Pemetrexed Phase 2
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: pemetrexed 900 mg/m2 IV on Day 1 of each 21-day treatment cycle and supportive medications (folic acid, vitamin B12, and dexamethasone).
Study: NCT04958239
Drug: BI 765179
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 765179
Study: NCT04958239
Drug: Ezabenlimab
Normalized name: Ezabenlimab
DrugBank: Ezabenlimab (DB17483)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezabenlimab
Study: NCT04958239
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pembrolizumab
Study: NCT06793813
Drug: cadonilimab，bevacizumab，docetaxel
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients receive Cadonilimab IV over 90 minutes on day 1. Patients also receive bevacizumab 7.5mg/kg IV on day 1 and docetaxel 60-75 mg/m2 IV over 60 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Study: NCT05937906
Drug: Phase I - Mirdametinib - Level 1
Normalized name: mirdametinib 1 MG
DrugBank: Mirdametinib (DB07101)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirdametinib 4 mg twice/day for 7 days per cycle
Study: NCT05937906
Drug: Phase II - Mirdametinib
Normalized name: Mirdametinib
DrugBank: Mirdametinib (DB07101)
Approvals — FDA: no, EMA: no, PMDA: no
Description: For phase 2 : Randomisation with 2 arm : Standard arm and experimental arm
Study: NCT05937906
Drug: Phase I - Mirdametinib - Level 2
Normalized name: mirdametinib 2 MG
DrugBank: Mirdametinib (DB07101)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirdametinib 4 mg twice/day for 14 days per cycle
Study: NCT05937906
Drug: Phase I - Mirdametinib - Level 3
Normalized name: Mirdametinib
DrugBank: Mirdametinib (DB07101)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirdametinib 6 mg twice/day for 7 days per cycle
Study: NCT05937906
Drug: Phase I - Mirdametinib - Level 4
Normalized name: Mirdametinib
DrugBank: Mirdametinib (DB07101)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirdametinib 6 mg twice/day for 14 days per cycle
Study: NCT06333899
Drug: Lorlatinib
Normalized name: LORLATINIB
DrugBank: Lorlatinib (DB12130)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Continue maintenance monotherapy for total 12 cycles
Study: NCT06333899
Drug: Lorlatinib with chemotherapy1
Normalized name: LORLATINIB
DrugBank: Lorlatinib (DB12130)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Continue lorlatinib with BABY-POG chemotherapy backbone for 72 weeks
Study: NCT06333899
Drug: Lorlatinib with chemotherapy 2
Normalized name: LORLATINIB
DrugBank: Lorlatinib (DB12130)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Continue lorlatinib with HIT-SKK chemotherapy backbone for 42 weeks
Study: NCT04878029
Drug: Cabozantinib S-malate
Normalized name: Cabozantinib S-Malate
DrugBank: Cabozantinib (DB08875)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT04878029
Drug: Enfortumab Vedotin
Normalized name: ENFORTUMAB VEDOTIN
DrugBank: Enfortumab vedotin (DB13007)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT04899674
Drug: Elontril
Normalized name: phendimetrazine tartrate Oral Tablet [Bontril]
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablet
Study: NCT04899674
Drug: BI 1358894
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Film coated tablet
Study: NCT06757244
Drug: Dostarlimab
Normalized name: Dostarlimab
DrugBank: Dostarlimab (DB15627)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intra-venous (i.v) dostarlimab: day1 - d21: 500mg IV q3Weeks (cycle 1 to cycle 4) then 1000 mg IV q6Weeks (from cycle 5 onwards)
Study: NCT06757244
Drug: Vitamin D3 (Cholecalciferol)
Normalized name: vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vitamin D3 8000 IU/d for 14 days, then 4000IU/d
Study: NCT06755151
Drug: Fenofibrate
Normalized name: Fenofibrate
DrugBank: Fenofibrate (DB01039)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fenofibrate 200mg
Study: NCT01370447
Drug: EPI-743
Normalized name: 8-epi-cyanocobalamin
DrugBank: 8-epi-Cyanocobalamin (DB14092)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPI-743 (oral solution \[100 mg/mL\] or liquid-filled capsules \[100 mg or 200 mg\]) will be administered per dose and schedule specified in the arm.
Study: NCT05926180
Drug: DZD9008 and Probe drugs (midazolam, digoxin, rosuvastatin)
Normalized name: rosuvastatin and ezetimibe
DrugBank: Ezetimibe (DB00973)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients will receive single oral doses of probe drugs alone and after at least 27 days of treatment with DZD9008, 300 mg, once daily, until a treatment discontinuation criterion is met. Each patient will receive a single oral dose of DZD9008 on Day 7, and DZD9008 once daily for 27 days from Day 9 to Day 35. Patients will also receive a single oral dose of 2 mg midazolam on Day 1 and Day 32, and oral dose of 10 mg rosuvastatin and 0.25 mg digoxin cocktail on Day 2, Day 7 and Day 33.
Study: NCT06760637
Drug: PF-07220060
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CDK4 inhibitor
Study: NCT06760637
Drug: letrozole
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: endocrine therapy
Study: NCT06760637
Drug: abemaciclib
Normalized name: Abemaciclib
DrugBank: Abemaciclib (DB12001)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: CDK4/6 inhibitor
Study: NCT06760637
Drug: palbociclib
Normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: CDK4/6 inhibitor
Study: NCT06760637
Drug: ribociclib
Normalized name: Ribociclib
DrugBank: Ribociclib (DB11730)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: CDK4/6 inhibitor
Study: NCT05383495
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intranasal dexmedetomidine 3 mcg/kg \[100 mcg/mL (max 200 mcg or 2 mL)
Study: NCT05383495
Drug: Midazolam Nasal Spray
Normalized name: midazolam Nasal Spray
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intranasal midazolam 0.4 mg/kg \[5 mg/mL (max 10 mg or 2 mL)
Study: NCT05383495
Drug: Nitrous oxide
Normalized name: Nitrous Oxide
DrugBank: Nitrous oxide (DB06690)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50% nitrous oxide in 50% oxygen by face mask
Study: NCT06767150
Drug: a rescue second infusion at month-12 (standard traitment)
Normalized name: crospovidone (12 MPA.S at 5%)
DrugBank: Povidone (DB11061)
Approvals — FDA: no, EMA: no, PMDA: no
Description: a first infusion of ZOL 5 mg, 6 months after denosumab withdrawal (= study start), and potentially a rescue second infusion at month-12, in case unfavourable outcome (incident osteoporotic fractures) or high risk of unfavourable outcome
Study: NCT06761768
Drug: Corticosteroids Triamcinolone Acetonide
Normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ultrasound-guided sacroiliac joint corticosteroid injections (1 ml SHINCORT INJ 10 MG/ML + 1 ml 2% Xylocaine)
Study: NCT06762782
Drug: Postoperative adjuvant lenvatinib
DrugBank: Lenvatinib (DB09078)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Follow the instructions and take lenvatinib 8 mg (body weight ≤ 60Kg) or 12 mg (body weight ≥ 60Kg) orally once a day.
Study: NCT06763926
Drug: Subcutaneous Triptorelin
DrugBank: Triptorelin (DB06825)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oocyte donors will undergo progesterone-primed ovarian stimulation according to the standard operating protocol for the clinical unit. Specifically, on day 1 or 2 of the menstrual cycle, a transvaginal ultrasound will be performed to check the antral follicle count (AFC) and the absence of follicles \>10mm. For participants taking oral contraceptives before the treatment, the pill-free interval before starting ovarian stimulation will be 5 days. Participants will administer exogenous gonadotropins (recombinant or urinary), along with 200mg oral micronized progesterone per day for pituitary suppression. Participants using any commercially available gonadotropin preparation will be eligible for inclusion.~Once 3 follicles ≥18mm are observed, participants will be randomised to one of the study arms.~In the control group, 200 mcg subcutaneous triptorelin will be administered 34-36 hours prior to planned oocyte collection.
Study: NCT06763926
Drug: Intranasal nafarelin
DrugBank: Nafarelin (DB00666)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oocyte donors will undergo progesterone-primed ovarian stimulation according to the standard operating protocol for the clinical unit. Specifically, on day 1 or 2 of the menstrual cycle, a transvaginal ultrasound will be performed to check the antral follicle count (AFC) and the absence of follicles \>10mm. For participants taking oral contraceptives before the treatment, the pill-free interval before starting ovarian stimulation will be 5 days. Participants will administer exogenous gonadotropins (recombinant or urinary), along with 200mg oral micronized progesterone per day for pituitary suppression. Participants using any commercially available gonadotropin preparation will be eligible for inclusion.~Once 3 follicles ≥18mm are observed, participants will be randomised to one of the study arms.~In the experimental group, 800 mcg intranasal nafarelin will be administered 34-36 hours prior to planned oocyte collection.
Study: NCT06763094
Drug: Tranexamic Acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic Acid stands out due to its non-hormonal action in managing menorrhagia, providing an alternative for women who are contraindicated for hormonal treatments or prefer non-hormonal solutions. Unlike other hormonal treatments, Tranexamic Acid does not impact fertility or have significant endocrine effects.
Study: NCT06768320
Drug: Lomaira 8Mg Tablet
Normalized name: Lomaira 8mg Tablet
DrugBank: Phentermine (DB00191)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 8 mg tablet up to three times a day
Study: NCT06773364
Drug: Levetiracetam
Normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intervention group - to commence IV levetiracetam 500mg as a single bolus in the ambulance, and then to continue as levetiracetam 500mg bid orally after admission to hospital in those with confirmed acute stroke for the next 14 days (at least 7 days if either dead or discharged from hospital if earlier). They will also receive standard management of acute stroke, whether the final diagnosis is ischaemic or ICH
Study: NCT06773403
Drug: Upadacitinib
Normalized name: Upadacitinib
DrugBank: Upadacitinib (DB15091)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: All subject start on 15mg. At week 8 subjects may increase to 30mg if the investigators deems it necessary.
Study: NCT06773221
Drug: Chiglitazar 64mg
Normalized name: Chiglitazar
DrugBank: Chiglitazar (DB19023)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chiglitazar 64mg, oral, qd, for 72 weeks
Study: NCT06323837
Drug: Mirtazapine
Normalized name: Mirtazapine
DrugBank: Mirtazapine (DB00370)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: This is a Phase 2, randomized, double-blind, placebo-controlled clinical trial (RCT) to evaluate the ability of mirtazapine (MZP) to increase methamphetamine (MA) abstinence among treatment-seeking medication for opioid use disorder (MOUD) adults.
Study: NCT04715568
Drug: Losartan
Normalized name: Losartan
DrugBank: Losartan (DB00678)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 mg tablets taken orally
Study: NCT04674241
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ten minutes after anesthesia induction and endotracheal intubation, patients assigned to dexmedetomidine group were given a loading dose of dexmedetomidine 0.6 μg/kg over 10 minutes, followed by continuous infusion at a rate of 0.4 μg/kg/h until the start of dural closure.
Study: NCT05946811
Drug: Macitentan 10mg
Normalized name: MACITENTAN 10MG TAB
DrugBank: Macitentan (DB08932)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Macitentan 10 mg oral once daily for 3 months. vs placebo
Study: NCT05142267
Drug: Oxycodone
Normalized name: Oxycodone
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: In randomized order (crossover) across 3 laboratory sessions, participants will undergo laboratory evoked thermal pain response testing with: 1) 0.13 mg/kg of oral oxycodone (in 1mg/ml syrup) plus 20ml i.v. saline placebo, 2) 8mg of i.v. naloxone (in 20ml saline vehicle) plus oral placebo syrup (quantity matching oxycodone syrup volume), or 3) 20ml i.v. saline placebo plus oral placebo syrup (quantity matching oxycodone syrup volume).~Thermal pain testing utilizes a Medoc TSAII NeuroSensory Analyzer. This equipment is used to assess heat pain threshold and tolerance using an ascending method of limits protocol.
Study: NCT05142267
Drug: Naloxone
Normalized name: Naloxone
DrugBank: Naloxone (DB01183)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In randomized order (crossover) across 3 laboratory sessions, participants will undergo laboratory evoked thermal pain response testing with: 1) 0.13 mg/kg of oral oxycodone (in 1mg/ml syrup) plus 20ml i.v. saline placebo, 2) 8mg of i.v. naloxone (in 20ml saline vehicle) plus oral placebo syrup (quantity matching oxycodone syrup volume), or 3) 20ml i.v. saline placebo plus oral placebo syrup (quantity matching oxycodone syrup volume).~Thermal pain testing utilizes a Medoc TSAII NeuroSensory Analyzer. This equipment is used to assess heat pain threshold and tolerance using an ascending method of limits protocol.
Study: NCT05888597
Drug: L-menthol
Normalized name: L-menthol
DrugBank: Levomenthol (DB00825)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: (Sigma-Aldrich, St. Louis, US)
Study: NCT06550414
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Active comparator: dexmedetomidine group
Study: NCT06550414
Drug: Bupivacain
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Placebo comparator: bupivacaine group
Study: NCT05013008
Drug: Finerenone (Kerendia, BAY94-8862)
Normalized name: Finerenone
DrugBank: Finerenone (DB16165)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral tablet; starting at 10 mg or 20 mg; once daily; received in previous interventional Phase 3 trial FIGARO-DKD; no new intervention was administered in this biomarker study.
Study: NCT06470854
Drug: Nebulized Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Nebulized Dexmedetomidine was prepared to provide 1 µg/kg and the calculated dose of DXM was diluted by 4-ml of 0.9% saline and was provided in the nebulizer to be nebulized in twice daily; i.e. every 12 hours for 72 hours
Study: NCT05356858
Drug: zanubrutinib
Normalized name: Zanubrutinib
DrugBank: Zanubrutinib (DB15035)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: zanubrutinib orally, 80mg bid for 1 year
Study: NCT06779253
Drug: pimicotinib capsules
Normalized name: Pimicotinib
DrugBank: Pimicotinib (DB18972)
Approvals — FDA: no, EMA: no, PMDA: no
Description: the effect of multiple oral doses of pimicotinib (50 mg QD) on the pharmacokinetics of fexofenadine (P-gp sensitive substrate), rosuvastatin (BCRP sensitive substrate) and metformin (MATE1 sensitive substrate). Fexofenadine and rosuvastatin will be administered together as a cocktail, and metformin will be given via staggered dosing from the cocktail drugs administration
Study: NCT06780124
Drug: ZE63-0302 or placebo
Normalized name: INV-CSP #2002 METFORMIN OR PLACEBO
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: The participants will receive ZE63-0302 or placebo
Study: NCT06541262
Drug: Silmitasertib
Normalized name: Silmitasertib
DrugBank: Silmitasertib (DB15408)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules
Study: NCT06541262
Drug: Irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV
Study: NCT06541262
Drug: Temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral
Study: NCT06541262
Drug: Vincristine
Normalized name: Vincristine
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV
Study: NCT06781255
Drug: Kamuvudine-9
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 96 mg tablets taken twice a day for 4 weeks
Study: NCT06752603
Drug: ONO-1110
Normalized name: ONO-2952
DrugBank: ONO-2952 (DB14802)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ONO-1110 tablets once a day
Study: NCT06765265
Drug: Atorvastatin 40 mg
Normalized name: atorvastatin 40 MG
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atorvastatin 40mg / Day for 24 weeks
Study: NCT05264883
Drug: Venetoclax-Decitabine/Azacitidine-Aclarubicin Association
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Treatment with Venetoclax+Decitabine/Azacitidine+Aclarubicin
Study: NCT05264883
Drug: Venetoclax-Decitabine/Azacitidine Association
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Treatment with Venetoclax+Decitabine/Azacitidine
Study: NCT06170697
Drug: Camrelizumab
Normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200mg, iv, d1, q3w
Study: NCT04811092
Drug: Sotatercept
Normalized name: Sotatercept
DrugBank: Sotatercept (DB12118)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sotatercept (ACE-011) is a recombinant fusion protein consisting of the extracellular domain of the human activin receptor type IIA linked to the Fc piece of human IgG1
Study: NCT06170697
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 80-100mg/m2, iv, q3w, 2-3 cycles in total
Study: NCT06170697
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: AUC 2, iv, q1w, 5-7 cycles in total
Study: NCT06170697
Drug: Lobaplatin
Normalized name: Lobaplatin
DrugBank: Lobaplatin (DB13049)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30mg/m2, iv, q3w, 2-3 cycles in total
Study: NCT06170697
Drug: Nedaplatin
Normalized name: Nedaplatin
DrugBank: Nedaplatin (DB13145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25-30 mg/m2, iv, q1w, 5-7 cycles in total
Study: NCT06263452
Drug: Propranolol
Normalized name: Propranolol
DrugBank: Propranolol (DB00571)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablet encapsulated to visually look identical to the placebo.
Study: NCT06768658
Drug: TAK-951
Normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-951 subcutaneous injection.
Study: NCT06132256
Drug: Axatilimab
Normalized name: Axatilimab
DrugBank: Axatilimab (DB16388)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as intravenous (IV) infusion
Study: NCT05105997
Drug: Dexamethasone/ Erector Spinae Plane Block
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients will receive bilateral Ultrasound-guided Erector Spinae Plane Block with bupivacaine and dexamethasone 15 minutes before skin incision
Study: NCT05105997
Drug: Erector Spinae Plane Block
Normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive bilateral Ultrasound-guided Erector Spinae Plane Block with bupivacaine and one ml of normal saline 15 minutes before skin incision.